Associated Papers
A common druggable signature of oncogenic c-Myc, mutant KRAS and mutant p53 reveals functional redundancy and competition among oncogenes in cancer.
Grześ M et al.
Cell Death & Disease, 2024
39217152 (PubMed )
Supplement: 41419_2024_6965_MOESM1_ESM.pdf
Concurrent NRAS-BRAF variants in metastatic colorectal cancer: a Tunisian case report.
Douik H et al.
Anti-cancer Drugs, 2024
Source, co-occurrence, and prognostic value of PTEN mutations or loss in colorectal cancer.
Serebriiskii IG et al.
Npj Genomic Medicine, 2023
38001126 (PubMed )
Supplement: 41525_2023_384_MOESM1_ESM.xlsx › Table_S8
Clinico-pathological associations and concomitant mutations of the RAS/RAF pathway in metastatic colorectal cancer.
Isnaldi E et al.
Journal of Translational Medicine, 2019
DNA sequence profiles of the colorectal cancer critical gene set KRAS-BRAF-PIK3CA-PTEN-TP53 related to age at disease onset.
Berg M et al.
Plos One, 2010
21103049 (PubMed )
Supplement: pone.0013978.s002.xls › Table_S2
Select a paper to view details